Form | Tablet |
Manufacturer | Intas Pharmaceuticals |
Packaging Size | strip |
Composition | posaconazole |
Prescription/Non prescription | Prescription |
Minimum Order Quantity | 2 Piece |
Strength | 100 mg |
packing | 21 capsules |
composition | palbociclib capsule 100mg |
brand | shilpa medicare |
prescription / non-prescription | prescription |
Ciclib 125 mg is a targeted therapy containing the active constituent palbociclib. It belongs to the group of anticancer medications known as cyclin-dependent kinase inhibitors. It is used in treating hormone receptor-positive, human epidermal growth factor 2 negative advanced or metastatic (has spread to other parts of the body) breast cancer. Cancer is a condition in which cells multiply in an uncontrolled and abnormal manner. It is given in combination with certain other anticancer medications.
The common side effects that are likely to associate with Ciclib 125 mg are nausea, vomiting, diarrhea, tiredness, hair loss, dry skin, rash, infections, nose bleed, decreased appetite, low blood cell counts, swelling of lips and mouth, changes in taste, dry eye, blurred vision, and increased tearing. Inform your doctor if any of these side effects disturb or persist in you.
Inform your healthcare provider if you are allergic to Ciclib 125 mg and its ingredients. Before taking this medicine, it is vital to inform your doctor if you have any signs of infections (fever, chills, or sore throat), liver disorders, kidney disorders, or intolerance to some sugars. Consult your physician immediately if you experience symptoms such as dry cough, chest pain, or difficulty breathing, as it could indicate lung inflammation. Make sure you inform your physician of all the medicines, including supplements and herbal medicines; you are taking before you start treatment with this medication. Use effective birth control during the treatment and at least three weeks after the last dose. It is not recommended for adolescents and children under 18 years of age.
Minimum Order Quantity | 5 Stripe |
Dose/Strength | 400 mg |
Manufacturer | ZYDUS |
Composition | IMATINIB TABLETS |
Brand | IMAT 400MG |
Packaging Size | 12*10 |
Researchers have developed a new type of radiotherapy called Intensity Modulated Arc Therapy (IMAT). This allows radiotherapy to be directed more accurately at the cancer. Doctors think that using IMAT means a higher dose of radiotherapy can be given so the treatment might be better at killing the cancer cells.